• Concanamycin A: Selective V-ATPase Inhibitor for Cancer R...

  2026-02-19

  Concanamycin A is a potent, highly selective V-type H+-ATPase inhibitor, widely used in cancer biology research for its nanomolar efficacy and apoptosis induction in tumor cells. This article details its mechanistic action, experimental benchmarks, and critical workflow considerations for optimal use in V-ATPase-mediated pathway studies.

• KPT-330 (Selinexor): Selective CRM1 Inhibitor for Precisi...

  2026-02-18

  KPT-330 (Selinexor) is a highly selective, orally bioavailable CRM1 inhibitor that induces apoptosis and cell cycle arrest in various cancer models. Leveraging robust mechanistic and preclinical evidence, this compound has demonstrated potent anti-tumor activity in vitro and in vivo, particularly in non-small cell lung cancer and triple-negative breast cancer. APExBIO offers KPT-330 (B1464) as a research-grade tool for advanced oncology workflows.

• PPT (Propyl Pyrazole Triol): Selective ERα Agonist for Ta...

  2026-02-18

  PPT (Propyl Pyrazole Triol) is a highly selective ERα agonist that enables precise dissection of estrogen receptor signaling in cellular and in vivo models. Its selectivity, potency, and stability make it an essential tool for hormone receptor research and breast cancer studies. APExBIO's B6735 kit provides validated, reproducible results in ERα-centric workflows.

• SB743921: A Potent KSP Inhibitor for Advanced Cancer Rese...

  2026-02-17

  SB743921 stands out as a potent, selective kinesin spindle protein inhibitor, enabling precise modulation of mitotic spindle assembly and cell cycle arrest in diverse cancer research settings. This article delivers actionable guidance for integrating SB743921 into optimized workflows, troubleshooting common pitfalls, and leveraging its unique advantages in both in vitro and in vivo models.

• Filipin III (SKU B6034): Reliable Cholesterol Detection f...

  2026-02-17

  This article delivers actionable, scenario-driven guidance for membrane cholesterol visualization, with a focus on Filipin III (SKU B6034). Addressing key workflow challenges, it demonstrates how Filipin III supports reproducibility, specificity, and robust data interpretation in cell viability and cytotoxicity assays. Practical answers are grounded in current literature and the unique attributes of APExBIO’s Filipin III.

• KPT-330 (Selinexor): Mechanistic Insights and Emerging Ro...

  2026-02-16

  Explore the advanced mechanism of KPT-330 (Selinexor), a selective CRM1 inhibitor, and its unique potential for targeting nuclear export pathways in cancer research. This in-depth article offers fresh insights into apoptosis induction, tumor suppression, and future applications beyond existing guides.

• 7ACC2 and the Next Frontier in Tumor Immunometabolism: St...

  2026-02-16

  Explore how 7ACC2, a carboxycoumarin MCT1 inhibitor from APExBIO, is transforming cancer metabolism research by disrupting lactate and mitochondrial pyruvate transport. This in-depth article contextualizes recent immunometabolic findings, including the metabolic education of tumor-associated macrophages, and provides actionable strategies for translational researchers to leverage 7ACC2 in next-generation oncology workflows.

• NSC-23766: Mechanistic Precision and Strategic Leverage i...

  2026-02-15

  Explore how NSC-23766, a selective Rac GTPase inhibitor from APExBIO, is revolutionizing translational research by enabling precise dissection of Rac1 signaling, targeted apoptosis in cancer cells, and novel co-targeting strategies. This thought-leadership article advances the discussion beyond standard product summaries, providing mechanistic insights, experimental best practices, and strategic guidance for integrating Rac1 pathway inhibition into oncology, stem cell, and barrier function research.

• Concanamycin A: Disrupting Intracellular pH for Advanced ...

  2026-02-14

  Explore the scientific frontier of Concanamycin A as a selective V-type H+-ATPase inhibitor for cancer research. This in-depth guide uncovers new metabolic insights and advanced applications in apoptosis induction, setting it apart from conventional perspectives.

• PPT (Propyl Pyrazole Triol): A Benchmark Selective ERα Ag...

  2026-02-13

  PPT (Propyl Pyrazole Triol) is a highly selective estrogen receptor alpha agonist, enabling precise dissection of ERα-mediated pathways. Its robust selectivity and defined biochemical profile make it an essential tool for hormone receptor and breast cancer research.

• Recombinant Human Growth Hormone (GH): Molecular Mechanis...

  2026-02-13

  Recombinant Human Growth Hormone (GH), a primary somatotropic hormone, is a validated tool for pituitary growth hormone research and cell proliferation assays. Its mechanism involves IGF-1 pathway activation via IGFBP2-THBS1 regulation, supporting its use in endocrinology and growth hormone deficiency research. This article details molecular actions, experimental benchmarks, and integration strategies for APExBIO’s recombinant GH expressed in Escherichia coli.

• Saracatinib (AZD0530): Advanced Insights into Src/Abl Kin...

  2026-02-12

  Explore Saracatinib (AZD0530), a potent Src/Abl kinase inhibitor, with a deep dive into its molecular mechanisms, advanced research applications, and unique roles in both cancer and neurobiology. Discover how this compound enables novel experimental strategies beyond standard protocols.

• Carboplatin (SKU A2171): Reliable Solutions for Preclinic...

  2026-02-12

  This article delivers an in-depth, scenario-driven exploration of how Carboplatin (SKU A2171) meets real laboratory challenges in cancer research. By addressing cell viability, proliferation, and cytotoxicity assay pitfalls, we highlight workflow optimizations anchored in peer-reviewed data and practical expertise. Researchers gain actionable guidance on leveraging Carboplatin’s unique properties for reproducible, quantitative results.

• 7ACC2: Carboxycoumarin MCT1 Inhibitor for Advanced Cancer...

  2026-02-11

  7ACC2, a potent carboxycoumarin MCT1 inhibitor from APExBIO, empowers researchers to disrupt lactate and pyruvate transport in cancer cells, targeting metabolic vulnerabilities with dual-pathway specificity. This guide delivers actionable protocols, troubleshooting strategies, and scenario-driven insights to accelerate breakthroughs in cancer metabolism research and immunometabolic modulation.

• MTT Tetrazolium Salt: Advanced Insights for Chemoradiatio...

  2026-02-11

  Discover how MTT, a leading tetrazolium salt for cell viability assays, enables precise metabolic activity measurement in modern cancer research and chemoradiation models. This article delivers advanced scientific context, integrating groundbreaking applications and technical distinctions not found in standard reviews.

423 records 19/29 page Previous Next First page 上5页 1617181920 下5页 Last page